Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 76 to 90 of 147 results for sclerosis

  1. Percutaneous posterior tibial nerve stimulation for overactive bladder syndrome (HTG235)

    Evidence-based recommendations on percutaneous posterior tibial nerve stimulation for overactive bladder syndrome. This involves inserting a fine needle into a nerve just above the ankle and passing a mild electric current to the nerves that control bladder function.

  2. What non-pharmacological interventions are effective in reducing spasticity in people with Multiple Sclerosis (MS)?

    interventions are effective in reducing spasticity in people with Multiple Sclerosis (MS)? Any explanatory notes(if applicable)...

  3. Multiple long-term conditions: medication review (IND207)

    This indicator covers the percentage of patients with moderate or severe frailty and/or multimorbidity who have received a medication review in the last 12 months which is structured, has considered the use of a recognised tool and taken place as a shared discussion. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM186

  4. Neuropathic pain in adults: pharmacological management in non-specialist settings (CG173)

    This guideline covers managing neuropathic pain (nerve pain) with pharmacological treatments (drugs) in adults in non-specialist settings. It aims to improve quality of life for people with conditions such as neuralgia, shingles and diabetic neuropathy by reducing pain and promoting increased participation in all aspects of daily living. The guideline sets out how drug treatments for neuropathic pain differ from traditional pain management.

  5. What is the optimal frequency, intensity and form of rehabilitation for mobility problems in people with Multiple Sclerosis (MS)?

    and form of rehabilitation for mobility problems in people with Multiple Sclerosis (MS)? Any explanatory notes(if applicable) Reduced...

  6. Injectable bulking agents for faecal incontinence (HTG135)

    Evidence-based recommendations on injectable bulking agents for faecal incontinence. This involves injecting a material into the muscles around the anus to bulk the sides of the sphincter.

  7. Published guidance, NICE advice and quality standards

    Browse the complete list of all our published health and social care guidance, including guidelines, NICE advice and quality standards

  8. Prioritisation board decisions 2024

    Our centralised approach to prioritising guidance topics ensures that we produce guidance that is relevant, timely, accessible, and has demonstrable impact.

  9. Amyotrophic lateral sclerosis - SAR443820 [ID6386]

    Discontinued Reference number: GID-TA11476

  10. NICE visualisation of treatment options incorporating technology appraisals: interim process guide (PMG38)

    This process guide explains how treatment option summaries for multiple guidelines were developed in an open, transparent, and timely way, with appropriate expert input

  11. Pegcetacoplan for amyotrophic lateral sclerosis [TSID10594]

    In development Reference number: GID-TA11310 Expected publication date: TBC

  12. Functional electrical stimulation for drop foot of central neurological origin (HTG178)

    Evidence-based recommendations on functional electrical stimulation for drop foot of central neurological origin. This involves stimulating the peripheral nerves that supply the paralysed muscle using electrodes to restore muscular function.

  13. Is intravenous methylprednisolone more clinically and cost effective than oral methylprednisolone in people with relapsing–remitting Multiple Sclerosis (MS) and people with secondary progressive MS with continued relapses?

    than oral methylprednisolone in people with relapsing–remitting Multiple Sclerosis (MS) and people with secondary progressive MS with...

  14. Deep brain stimulation for tremor and dystonia (excluding Parkinson's disease) (HTG122)

    Evidence-based recommendations on deep brain stimulation for tremor and dystonia (excluding Parkinson's disease). This involves planting electrodes in the brain and generating electrical currents to help control the tremor or dystonia.

  15. NICE recommends that a new model for multiple sclerosis is developed, ideally based on UK patient cohorts, which uses the best available evidence (including experience to date from the risk-sharing scheme) and includes all currently available treatments.

    TA254/2 Question NICE recommends that a new model for multiple sclerosis is developed, ideally based on UK patient cohorts, which uses...